1stOncology™: Cancer Intelligence Service – Page 17 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240’s Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window

On June 11, 2026 Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage oncology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, reported the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at the European Association for Cancer Research (EACR) 2026 Annual Congress, being held June 8-11, 2026, in Budapest, Hungary.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A non-GLP toxicology study in NHPs validates the CAPTN-3 masking strategy and supports the planned advancement of IM1240 toward a first-in-human clinical study in 2027. Additionally, efficacy data in patient-derived samples from PD-1-resistant head and neck squamous cell carcinoma (HNSCC) metastatic lymph nodes, NSCLC and bladder cancer, generated in collaboration with the laboratory of Dr. Amir Horowitz at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, highlight the essential role of the NKG2A arm in IM1240-mediated anti-tumor immunity and further strengthen CAPTN-3’s differentiation and clinical potential.

Poster Title: Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window

Abstract: EACR26-0695

Session: Immunotherapy

Date: Wednesday, June 10, 2026

Summary of data presented at EACR 2026:

● IM1240 induced apoptosis of PD-1-resistant patient-derived biopsies from six HNSCC metastatic lymph node samples and one enfortumab vedotin/pembrolizumab-resistant muscle-invasive bladder cancer sample, with both the CD3 and NKG2A functional arms required for full activity.

● In a PD-1/chemotherapy-resistant NSCLC patient-derived explant, IM1240 induced mature tertiary lymphoid structures (TLS) – immune cell organizations associated with effective anti-tumor immunity and favorable clinical prognosis – while increasing CD8 T cell and NK cell abundance and reducing regulatory T cells (Tregs) and tumor cells. These effects were not observed with IM1340, the NKG2A loss-of-function variant, underscoring the essential and differentiated contribution of the NKG2A arm.

● In a non-GLP dose-range finding toxicology study in NHPs, IM1240 demonstrated markedly superior pharmacokinetics (PK) compared to the non-capped variant IM1222, including an approximately 8-fold longer half-life and 16-fold greater systemic exposure. IM1240 showed dose-proportional PK with a broad therapeutic window, as systemic exposure associated with tumor regression in mouse models remained well below the tolerated levels in NHPs.

● The CAPTN-3 masking strategy effectively mitigated peripheral T-cell activation and prevented systemic cytokine release in NHPs, which is associated with one of the main safety challenges of T-cell engagers, cytokine release syndrome (CRS):

○ IM1240 induced minimal IL-6 and TNF-α at 10 mg/kg dose, whereas the non-capped IM1222 induced robust cytokine release at just 0.03 mg/kg – a more than 300-fold difference in the dose required to trigger cytokine release.

○ The IM1240 capping design also improved the PK profile by reducing the CD3-mediated antigen sink effect and incorporating human serum albumin to further extend half-life, as compared to the non-capped variant IM1222.

○ IM1240 demonstrated ~14-fold slower clearance than active non-capped IM1222, supporting extended exposure and potential efficacy; rapid clearance of peripherally released non-capped IM1222 reduces systemic accumulation and lowers CRS risk and off-tumor toxicity.

"The preclinical data we are presenting at EACR 2026 demonstrate the full strength of the CAPTN-3 design. In NHPs, our masking strategy delivered markedly superior pharmacokinetics and an improved safety profile compared to the non-capped variant, establishing a broad therapeutic window that supports our planned path to the clinic." said Dr. Hadas Reuveni, VP R&D of Purple Biotech. "In collaboration with Dr. Amir Horowitz from Mount Sinai, we explored IM1240’s activity and mechanism of action in patient-derived tumors from PD-1/SoC-resistant patients. Data generated in Dr. Horowitz’s lab demonstrated cancer cell apoptosis induced by IM1240 across multiple PD1-resistant biopsies from HNSCC metastatic LN and muscle-invasive bladder cancer, where functional NKG2A and CD3 arms were both required for full activity, highlighting the potential of IM1240 design for patients who progressed on previous line/s of treatment. Additionally, we present for the first time tissue profiling analyses of NSCLC patient-derived explants showing that IM1240 treatment – unlike the NKG2A loss-of-function variant – drives substantial immune remodeling, characterized by the formation of mature tertiary lymphoid structures (TLS), a hallmark of effective anti-tumor immunity and favorable prognosis, along with increased CD8 T and NK cell abundance and reduced Treg levels.. These immune changes correlate with robust anti-tumor activity and underscored the critical contribution of the NKG2A arm, and further support IM1240’s potential to reprogram the tumor microenvironment and deliver meaningful clinical benefit in immunotherapy-resistant tumors."

(Press release, Purple Biotech, JUN 11, 2026, View Source [SID1234666570])

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

On June 11, 2026 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, reported it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock.

"With our recent advancements of the Company’s lead asset, PRP, towards entering the clinic with a novel, first-in-class cancer therapy to treat and prevent metastatic cancer from solid tumors with a pivotal Phase 1b, First-In-Human study in 30 to 40 advanced cancer patients, the management team believes we are entering a transformative stage for the Company. The work we’ve undertaken throughout this recent period, publishing key scientific data, filing patentable discoveries, forming partnerships with CRO’s, CDMO’s and suppliers, has us well positioned to advance PRP meaningfully and efficiently to achieve significant clinical milestones. This is further supported by US FDA Orphan Drug Designation for the treatment of pancreatic cancer which provides us with seven-year exclusivity in the market, post approval. The foundation is clearly there and as a result, we believe we are undervalued significantly," said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. "Furthermore, this decision reflects our commitment to disciplined, flexible capital allocation. Repurchases will be considered when we believe the market price meaningfully understates intrinsic value and when buybacks compete favorably relative to other uses of capital. We believe we are approaching such a position. Importantly, when executed thoughtfully, buybacks allow continuing shareholders to increase their ownership in the Company’s underlying assets, improve per share economics over time, and signal management’s confidence in the long-term value of the business, while still preserving the financial flexibility needed to pursue attractive opportunities as they arise."

Under the share repurchase program, the Company may buy back its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions, pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and federal and state laws governing such transactions, through a variety of methods, which may include open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of such methods. The repurchase program does not oblige the Company to acquire any specific number of shares and may be modified, discontinued, or suspended at any time.

(Press release, Propanc, JUN 11, 2026, View Source [SID1234666569])

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

On June 11, 2026 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported updated clinical data from the Company’s ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The data will be presented during an oral presentation at the 2026 EHA (Free EHA Whitepaper) Congress taking place June 11–14, 2026, in Stockholm, Sweden.

"These updated data continue to demonstrate the differentiated profile of bexobrutideg, including durable responses in heavily pretreated patients and encouraging activity in patients earlier in their treatment journey," said Talha Munir, M.B. Ch.B., Ph.D., consultant hematologist at Leeds Teaching Hospitals NHS Trust and deputy chair of the United Kingdom National Cancer Research Institute CLL Study Group. "Importantly, responses were observed across patients with difficult-to-treat disease characteristics, including BTK inhibitor resistance mutations, high-risk molecular features and CNS involvement, while maintaining a favorable tolerability profile."

"With longer follow-up in relapsed/refractory CLL and expansion into earlier-line treatment settings, we continue to see a consistent efficacy and safety profile for bexobrutideg," said Paula O’Connor, M.D., chief medical officer of Nurix. "The durability of responses observed in heavily pretreated patients together with the promising activity seen in BCL2i-naïve and BTKi-naïve patients further support the broad potential of BTK degradation across all lines of therapy in CLL."

"These latest findings continue to reinforce our belief that bexobrutideg has the potential to redefine BTK-directed therapy and emerge as a potentially best-in-class treatment for CLL," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix Therapeutics. "The updated data to be presented at EHA (Free EHA Whitepaper) across Phase 1 cohorts continue to support the launch of a broad Phase 3 monotherapy program and strengthen the rationale for exploring the use of combination regimens in first- and second-line patients. We look forward to advancing these programs through our recently announced collaboration with Roche."

Growing Safety Cohort Continues to Support Differentiated Profile
Across all Phase 1a/b CLL patients (n=142), bexobrutideg was well tolerated, consistent with prior disclosures, with safety findings generally comparable between patients treated at the 600 mg RP2D and the broader study population.

As of the January 1, 2026, data cutoff:
•No dose-limiting toxicities were observed
•No treatment-related Grade 5 adverse events were reported
•Treatment discontinuations due to adverse events occurred in only 5.6% of patients
•The most common treatment-emergent adverse events included purpura/contusion, neutropenia, petechiae, diarrhea, and fatigue.

Updated Phase 1a Data in Relapsed/Refractory CLL Continue to Support Durable Responses
The Phase 1a dose escalation study enrolled 48 patients with relapsed/refractory CLL/SLL treated with bexobrutideg at doses ranging from 50 mg to 600 mg once daily. Patients were heavily pretreated, having received a median of four prior lines of therapy (range 2–12), including prior BTK inhibitors (97.9%), prior BCL2 inhibitors (83.3%), and prior non-covalent BTK inhibitors (27.1%). Baseline high-risk features included BTK inhibitor resistance mutations (38.3%), TP53 mutations (44.7%), PLCG2 mutations (14.9%), and central nervous system (CNS) involvement (10.4%).

As of the January 1, 2026, data cutoff:
•Median follow-up was 22.4 months
•Median progression-free survival (PFS) was 22.1 months (95% CI: 14.0–NR)
•Objective response rate (ORR) was 83.0% (95% CI: 69.2–92.4)
•Responses included two complete responses, one nodal partial response, and 36 partial responses.
•Responses were observed across patients with BTK inhibitor resistance mutations, high-risk molecular features, and CNS involvement

Phase 1b Data Supports High ORR in Earlier-Line Cohorts
Nurix also presented new data from two of the Phase 1b cohorts evaluating bexobrutideg in earlier lines of treatment, including patients who had received prior BTKi treatment but were BCL2i-naïve (Cohort 5) and patients who were BTKi-naïve, including treatment-naïve patients (Cohort 15).

In Cohort 5 (n=19), patients had received prior BTK inhibitor therapy but no prior BCL2 inhibitor:
•ORR was 92.9% (95% CI: 66.1–99.8) among evaluable patients (n=14)
•18 of 19 patients remained on treatment at data cutoff
•Median follow-up was 5.2 months
•Five patients have not yet reached their first scan but remain on treatment

In Cohort 15 (n=20), which included BTKi-naïve and treatment-naïve patients:
•ORR was 84.2% (95% CI: 60.4–96.6) among evaluable patients (n=19)
•19 of 20 patients remained on treatment at data cutoff
•Median follow-up was 4.9 months
•Three patients with stable disease remain on treatment

About Bexobrutideg
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology.

Bexobrutideg is currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), and in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) in patients with relapsed or refractory B-cell malignancies. A new tablet formulation of bexobrutideg is also being evaluated in a first-in-human single-ascending-dose and multiple-ascending-dose study in healthy volunteers (NCT06717269) to support future development in immunology and neurology indications. Additional information about ongoing clinical trials can be found at clinicaltrials.gov.

(Press release, Nurix Therapeutics, JUN 11, 2026, View Source [SID1234666567])

FORUS Therapeutics Joins PharmaEssentia to Strengthen Focus on Hematology and Oncology in Canada

On June 11, 2026 FORUS Therapeutics Inc ("FORUS") reported that it has been acquired by PharmaEssentia Corporation, a global biopharmaceutical company focused on developing innovative therapies for hematology, oncology, and immunology.

This milestone builds on the successful collaboration established between FORUS and PharmaEssentia through the Canadian commercialization partnership for ropeginterferon alfa-2b, an investigational treatment currently under review by Health Canada for patients living with polycythemia vera (PV).

As part of PharmaEssentia, FORUS will continue to leverage its established expertise in the Canadian hematology and oncology environment while benefiting from expanded global resources and capabilities. The integration strengthens the combined organization’s ability to support regulatory, medical, market access, and commercial activities across Canada.

FORUS has built a strong reputation for bringing innovative therapies to Canadian patients and we look forward to continuing to do so alongside the Canadian healthcare community. The acquisition recognizes the value of the existing foundational partnership with Karyopharm and looks to create new opportunities to further support patients living with myeloproliferative neoplasms (MPNs) and other hematologic conditions.

"Our team is excited to become part of PharmaEssentia and to continue advancing our shared commitment to the Canadian hematology community," said Kevin Leshuk, Chief Executive Officer of FORUS Therapeutics. "Together, we are well positioned to build on our existing capabilities and support access to innovative treatment options for patients across Canada."

The FORUS team will continue its work with existing healthcare professionals, patient communities, and partners while supporting the advancement of PharmaEssentia’s growing hematology and oncology portfolio in Canada.

This transaction marks an important step in expanding the organization’s long-term presence in Canada and reinforces its commitment to improving outcomes for patients through scientific innovation and collaboration.

(Press release, FORUS Therapeutics, JUN 11, 2026, View Source;utm_medium=rss&utm_campaign=forus-therapeutics-joins-pharmaessentia-to-strengthen-focus-on-hematology-and-oncology-in-canada [SID1234666566])

Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

On June 11, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology platform, reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.

The new data demonstrates EVX-04’s complete expression in human cells, including correct transcription and translation. Further, EVX-04 is secreted in human cells, enabling immune recognition and activation.

The data also shows that all ERV antigens included in EVX-04 drive specific immune responses both in mice (in vivo) and human cells (in vitro) across different human immune profiles. These vaccine-induced immune cells mediate targeted cell-killing, highlighting EVX-04’s potential as a new effective therapeutic cancer vaccine.

Data will be presented at a poster presentation at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress taking place in Stockholm, Sweden, on June 13, 2026.

"We are excited to share the new data on EVX-04, which could potentially greatly improve treatment options for AML patients. We are successfully executing the preclinical activities and in parallel preparing the regulatory filing for clinical testing and are looking forward to discussing the data and the program at the EHA (Free EHA Whitepaper) congress," says Birgitte Rønø, CSO & COO of Evaxion.

About EVX-04
Developed with our AI-Immunology platform, EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome. These antigens are selectively expressed in specific tumors but absent in normal tissue, making them highly attractive therapeutic cancer targets.

Using sequencing data from AML patients, our AI-Immunology platform first identified ERV tumor antigens and then mined these to determine smaller fragments with the potential for immune recognition. From the five million ERV antigen fragments discovered, AI-Immunology combined and selected 16 optimal sets of ERV fragments based on their cross-patient relevance and immunogenic potential. All 16 ERV fragments included in EVX-04 elicit a specific immune response and EVX-04 prevents tumor growth in preclinical tumor models.

The data-driven target selection ensures that EVX-04 provides broad tumor coverage regardless of immune and tumor ERV antigen differences across patients. Thus, EVX-04 is developed as an off-the-shelf vaccine pre-produced and ready for immediate administration after diagnosis. The same concept is broadly applicable across cancers where immunotherapies remain inadequate and conserved immunogenic antigens can be identified.

About AML
AML is an aggressive hematologic malignancy characterized by clonal expansion of undifferentiated myeloid precursor cells (AML blasts) in the bone marrow. It has poor outcomes for patients ineligible for intensive chemotherapy or stem cell transplantation, highlighting the need for novel and less toxic treatment strategies.

AML is the most frequent leukemia, occurring across all age groups, however, predominantly observed in older adults (median age at diagnosis of 68 years).

Approximately 50% of patients, typically the elderly, are not fit for intensive treatment, so the standard of care is low-intensity chemotherapy. Remissions are, however, short lived with a 3‐year overall survival rate at only 25% reported (Kantarjian et al. 2025).

(Press release, Evaxion, JUN 11, 2026, View Source [SID1234666565])